Literature DB >> 26295975

Durations of military service after diagnoses of HIV-1 infections among active component members of the U.S. Armed Forces, 1990-2013.

John F Brundage, Devin J Hunt, Leslie L Clark.   

Abstract

This report describes the trends in length of military service for active component members of the U.S. Armed Forces who were diagnosed with human immunodeficiency virus type 1 (HIV-1) infections during 1990-2013. Durations of service after service members' initial diagnoses of HIV-1 infection were compared for five different cohorts that corresponded to when diagnoses were made during the 5-year intervals beginning in 1990, 1995, 2000, and 2005, and the 4-year interval of 2010-2013. By several measures, the durations of service after initial diagnoses of HIV-1 infection increased from the earliest to the later cohorts. The findings are discussed in the context of changes in several factors during the surveillance period: the growing availability and effectiveness of treatments for HIV-1 disease; the stigmas associated with the diagnosis of HIV-1 infection and its link to homosexuality; and the changes in U.S. military policy about the inclusion of homosexuals in its ranks. Also discussed are the limitations of the estimates for the most recent cohorts and the future prospects for continued lengthening of service for those infected with HIV-1.

Entities:  

Mesh:

Year:  2015        PMID: 26295975

Source DB:  PubMed          Journal:  MSMR        ISSN: 2152-8217


  2 in total

1.  The 3 levels of HIV stigma in the United States military: perspectives from service members living with HIV.

Authors:  Joseph M Yabes; Phillip W Schnarrs; Leroy B Foster; Paul T Scott; Jason F Okulicz; Shilpa Hakre
Journal:  BMC Public Health       Date:  2021-07-15       Impact factor: 3.295

2.  Antiretroviral Therapy and Viral Suppression Among Active Duty Service Members with Incident HIV Infection - United States, January 2012-June 2018.

Authors:  Shauna Stahlman; Shilpa Hakre; Paul T Scott; Brian K Agan; Donald Shell; Todd Gleeson; Jason M Blaylock; Jason F Okulicz
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-04-03       Impact factor: 17.586

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.